As the foundation of NCCN and ELN treatment guidelines, as well as a primary endpoint in phase 3 trials of second- and third-generation TKIs, peripheral blood BCR::ABL1 levels are integral to the clinical management of CML [8]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.